- Home
- CAVA vs EXAS Comparison
CAVA vs EXAS Comparison
Compare CAVA & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- EXAS
- Stock Information
- Founded
- CAVA 2006
- EXAS 1995
- Country
- CAVA United States
- EXAS United States
- Employees
- CAVA N/A
- EXAS N/A
- Industry
- CAVA Restaurants
- EXAS Medical Specialities
- Sector
- CAVA Consumer Discretionary
- EXAS Health Care
- Exchange
- CAVA Nasdaq
- EXAS Nasdaq
- Market Cap
- CAVA 15.6B
- EXAS 12.3B
- IPO Year
- CAVA 2023
- EXAS N/A
- Fundamental
- Price
- CAVA $134.25
- EXAS $71.05
- Analyst Decision
- CAVA Buy
- EXAS Strong Buy
- Analyst Count
- CAVA 14
- EXAS 13
- Target Price
- CAVA $116.23
- EXAS $79.00
- AVG Volume (30 Days)
- CAVA 1.7M
- EXAS 1.4M
- Earning Date
- CAVA 11-12-2024
- EXAS 11-05-2024
- Dividend Yield
- CAVA N/A
- EXAS N/A
- EPS Growth
- CAVA N/A
- EXAS N/A
- EPS
- CAVA 0.38
- EXAS N/A
- Revenue
- CAVA $845,224,000.00
- EXAS $2,612,011,000.00
- Revenue This Year
- CAVA $30.90
- EXAS $15.53
- Revenue Next Year
- CAVA $20.98
- EXAS $13.78
- P/E Ratio
- CAVA $367.35
- EXAS N/A
- Revenue Growth
- CAVA 31.01
- EXAS 13.54
- 52 Week Low
- CAVA $29.66
- EXAS $40.62
- 52 Week High
- CAVA $141.25
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- CAVA 55.09
- EXAS 55.81
- Support Level
- CAVA $135.74
- EXAS $68.61
- Resistance Level
- CAVA $141.25
- EXAS $71.49
- Average True Range (ATR)
- CAVA 3.48
- EXAS 1.91
- MACD
- CAVA -0.55
- EXAS -0.34
- Stochastic Oscillator
- CAVA 40.63
- EXAS 50.41
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.